Cargando…
Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer
BACKGROUND: The management of pancreatic cancer (PanCa) is exceptionally difficult due to poor response to available therapeutic modalities. Tubulins play a major role in cell dynamics, thus are important molecular targets for cancer therapy. Among various tubulins, βIII and βIV-tubulin isoforms hav...
Autores principales: | Kashyap, Vivek K., Wang, Qinghui, Setua, Saini, Nagesh, Prashanth K. B., Chauhan, Neeraj, Kumari, Sonam, Chowdhury, Pallabita, Miller, Duane D., Yallapu, Murali M., Li, Wei, Jaggi, Meena, Hafeez, Bilal Bin, Chauhan, Subhash C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343279/ https://www.ncbi.nlm.nih.gov/pubmed/30674344 http://dx.doi.org/10.1186/s13046-018-1009-7 |
Ejemplares similares
-
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021) -
Novel Paclitaxel Nanoformulation Impairs De Novo Lipid
Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy
por: Shetty, Advait, et al.
Publicado: (2020) -
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019) -
Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer
por: Chowdhury, Pallabita, et al.
Publicado: (2018) -
Indocyanine Green-based Glow Nanoparticles Probe for Cancer Imaging
por: Chauhan, Neeraj, et al.
Publicado: (2023)